PCRX and PTN Related Headlines
Go Back- PharmaCorp to acquire Ontario pharmacy for $8.2 million
- PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
- PharmaCorp acquires pharmacy files in western Canada for $300,000
- PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
- PharmaCorp to acquire eight pharmacies for $24.2 million
- PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
- PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
- PharmaCorp Announces Investor Relations Agreement
- PharmaCorp Rx Inc. To Present At The 2026 Bloom Burton & Co. Healthcare Investor Conference
- PharmaCorp Announces Grant of Stock Options
- PharmaCorp Announces Grant of Stock Options
- PharmaCorp Enters Letter of Intent for the Acquisition of Pharmacy Files in Western Canada
- Pharmacorp Rx Inc. Reports Q3 2025 Financial Results
- PharmaCorp appoints Paul Dale as president and COO
- PharmaCorp Announces Executive Transition and New Director of Business Development
- PharmaCorp Rx Inc. Files Final Short Form Base Shelf Prospectus
- PharmaCorp Refiles Q2 2025 Financial Statements
PCRX and PTN Related Press Releases
Go Back- PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
- PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
- PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
- PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
- PharmaCorp Announces Investor Relations Agreement
- PharmaCorp Rx Inc. To Present At The 2026 Bloom Burton & Co. Healthcare Investor Conference
- PharmaCorp Announces Grant of Stock Options
- PharmaCorp Announces Grant of Stock Options
- PharmaCorp Enters Letter of Intent for the Acquisition of Pharmacy Files in Western Canada
- Pharmacorp Rx Inc. Reports Q3 2025 Financial Results
- PharmaCorp Announces Executive Transition and New Director of Business Development
- PharmaCorp Rx Inc. Files Final Short Form Base Shelf Prospectus
- PharmaCorp Refiles Q2 2025 Financial Statements


